PPAR-γ agonists, such as thiazolidinediones, are beneficial for type 2 diabetes management; however, thiazolidinediones fell out of favor because of severe side effects such as adipose hypertrophy, edema, and coronary dysfunction [9]. Here, PPARG is linked to type 2 diabetes mellitus.